What does Lever Bio do?
Lever Bio is a biotechnology company focused on developing new immuno-oncology therapies by leveraging metabolic and immune system reprogramming to overcome resistance to existing cancer treatments, particularly in solid tumors.
How much did they raise?
The company secured €4M in funding led by Claris Ventures. Although the specific round type was not disclosed, the investment will support further progression of its assets through preclinical development.
What are their plans for the money?
With the new funds, Lever Bio plans to validate the therapeutic potential and optimal positioning of its biologics in treating solid tumors, potentially accelerating the availability of novel treatments for cancer patients.
What have they achieved so far?
Lever Bio has already established a strategic partnership with Belgium's VIB, gaining access to key intellectual property and collaborating with leading research institutions, alongside the expertise of Professor Massimiliano Mazzone, to develop four novel VHH antibody-based therapies.
